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Background: Acute mountain sickness is a major public health problem in high 
altitudes. Similarly, anecdotal evidence suggests that there is high prevalence of tobacco 
smoking among this group though prevalence of obstructive airflow limitation is not 
known. 
Objectives: The main aims of the study were to measure the awareness of AMS and 
report the prevalence of AMS and obstructive lung diseases in high altitude Nepalese 
porters.  
Setting: This study was done with bases in Namche Bazaar (3460metres), Pheriche 
(4270m), Thokla pass (4830m), Gorakshep (5140m) and Everest Base Camp (5364m). 
Method: A cross-sectional study was conducted using standardized multiple choice 
questionnaires among high altitude porters working at Namche and above during May-
June 2008. Total 200 porters were interviewed. Lake Louis questionnaire was used for 
diagnosis of AMS. Spirometry was performed in 160 porters at Namche Bazaar. 
Results: Awareness of AMS was medium among 50% of porters and 36% had low 
knowledge regarding AMS. The total prevalence of AMS was 4% among porters. The 
prevalence of AMS was 0.6% at 3460m, 13.3% at 4270m, 21.4% at 4830m and 28.5% at 
5364m.  Prevalence of tobacco smoking was 34%. Frequency of airflow limitation was 
17.9% which was defined by FEV1/FVC <0.7. Vital signs (BP, PR and RR) and 
saturation pressure of oxygen (SpO2) were significantly associated with AMS outcome 
(p-value <0.05). Age and smoking were not found to be associated with airflow 
limitation. 
Conclusion: The level of awareness regarding AMS in porters wain the middle range 
in Khumbu region. Prevalence of AMS was low compare to climbers and foreign 
trekkers. Prevalence of smoking was high but it was not related to airflow limitation. 
Airflow limitation might be due to open indoor fires used for cooking which is very 
common in this region and other hyperactive lung diseases. Different organizations 
working for porters should focus on awareness programmes regarding AMS and adverse 
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CHAPTER 1: INTRODUCTION 
1.1 Country profile  
Nepal is a landlocked country situated between China a d India in South Asia. It has a 
population of about 27 million people. Nepal is divi ed in five regions, fourteen zones 
and seventy-five districts administratively. Katmandu is the capital city [1] . 
For a long time, Nepal has been a favorite tourist destination due to its geographical 
variations from plains of Terai which is neighboring India to beautiful high Himalayas in 
north facing Tibet. Nepal is also famous in the world as “birthplace of Lord Buddha” and 
“Land of Himalayas”. It is the country of Mount Everest which is the highest peak in the 
world with a height of 8848 metres. Mount Everest, i  also known by the name of 
“Sagarmatha” (hat of the world) in Nepali language and  “Chomolungma” meaning 
Goddess mother of the Earth in Tibetan language [2].  
Many tourists from different parts of world travel to Nepal each year, for trekking and 
mountaineering in the Himalayas. It is the dream of many climbers to reach to the 
summit of Mt. Everest but only few succeeds. Since, N pal is one of the poorest 
countries in the world and due to its geographical diversities, traveling to Himalayas in 
Nepal is very difficult compared to western world.  
Many of the tourists and the trekkers are accompanied by Nepalese porters carrying their 
luggage. Carrying heavy loads in the high altitudes is a real challenge as well as risky. 
These porters are predominantly from ethnic groups like Sherpa, Rai, Tamang and 
Magar. Among these, Sherpa are famous  for mountain climbing and though many 
Sherpa work as porters in this region , not all porters are Sherpa [3] . 
1.2 Altitude and human settlement 
Approximately, around 140 million people around theworld live permanently at altitudes 
higher than 2500 meters [4, 5]. Presently, the highest settlement in the world is in the 
village of La Rinconada at 5100m in Peru. This is a mining village with almost seven 




For the ease of understanding, high altitude by consensus is categorized into three 
subdivisions such as “High altitude (1500m to 3500m), “Very High Altitude (3500m to 
5500m) and “Extreme Altitude (above 5500m) [7] . 
1.3 Normal physiologic changes in altitude 
On ascent to higher altitude, barometric pressure of oxygen decreases while the 
percentage of available oxygen in atmospheric air st ys at 21%. The partial pressure of 
oxygen determines the amount of oxygen available during each breath and with 
increasing altitude each breath will hold less oxygen [8]. 
Initially, the partial pressure of oxygen in the arterial blood (PaO2) falls parallel to the 
partial pressure in the atmosphere. When the falling PaO2 reaches critical level 
(approx.8kPa), chemo- receptors located in the carotid and aortic bodies start signaling 
for stimulating the increased ventilation, which in turn results in expelling of CO2 and 
lowering of PaCO2, ultimately raising the body pH. Both, low PaCO2 and high pH give 
a strong negative feedback on ventilation, limiting the ultimate effect of this immediate 
response to hypoxia [8]. Over days of this moderate hyperventilation, the kidneys 
respond by expelling buffer (bicarbonate) and thereby aiding the normalization of pH.  In 
turn, this again allows the ventilation to increase further [9].  Over the long term say 
weeks to months, the chronic hypoxia also stimulates th  production of hemoglobin and 
erythrocytes, increasing the blood capacity for O2 transport [8].    
Thus, the physiological response to hypobaric hypoxia consists of immediate, 
intermediate, and long term effects which in turn work to improve O2 delivery to body 
tissue and thus supporting body acclimatization to high altitude.  All of these 
mechanisms mentioned can also be related to pathophysiology of altitude sickness. 
1.4 Hypoxia of high altitude and barometric pressure  
Hypoxia is the main insult to the body in high altitude which finally develops AMS. The 
compensatory mechanisms help lot in acclimatization of body with low oxygen but do 
not totally prevent the effects of hypoxia. Hypoxia of high altitude impairs physical and 
mental performance and causes  sleep disturbance and fin lly develops AMS [8]. Figure 





Figure 1: Altitude, barometric pressure and inspired PO2 [Source: The physiologic basis of High-
Altitude Disease  
 
1.5 Literature review 
1.5.1 High altitude illness 
High Altitude illness refers to a collective term for Acute Mountain Sickness (AMS), 
High Altitude Cerebral Edema (HACE), and High Altitude Pulmonary Edema (HAPE) 
which affects unacclimatized travellers shortly after ascent to high altitude. Acute 
Mountain sickness is more frequent where as HAPE and HACE are less frequent but 
potentially fatal [9].  
1.5.2 Acute mountain sickness 
Acute mountain sickness  is a benign form of high altitude illness comprising mainly of  




and sleep disturbance [10-13]. Symptoms occur within 6-12 hours of ascent, on 
individuals who rapidly ascend over 2500m without sfficient acclimatization and varies 
in severity from mild to incapacitating [12]. 
Headache is the most common and most prominent symptom of AMS, although its cause 
remains unclear [10-14]. Non specific signs and sympto s of AMS can result in 
diagnostic confusion with other disorders such as exhaustion, dehydration, hypothermia, 
alcohol hangover and migraine [10].  
Anyone who goes to high altitude can get AMS. Certain individuals acclimatize quickly 
and can avoid AMS on further ascent while others cannot. The best way for prevention of 
mountain sickness is by ascending slowly and allowing enough time for body to 
acclimatize [8]. For prevention, Acetazolamide (Diamox) 125 mg twice daily can be 
prescribed otherwise the mainstay of treatment of AMS is rest, fluid and mild analgesics 
[7, 9]. 
1.5.3 High altitude cerebral edema (HACE) 
If the symptoms of AMS are neglected, then it can progress to HACE which is 
considered to be life threatening [15, 16]. HACE is severe form of AMS which is 
characterized by ataxia and altered consciousness which may progress to coma and can 
cause death due to brain herniation  [9-11, 17].  Persons with HACE are often found to be 
confused and may not recognize that they are ill. Usually, the illness progresses over a 
period of hours or days [18]. HACE usually appears during the night time and the 
individual with symptoms of HACE must be brought down to low altitude immediately. 
It is dangerous to wait further until the morning [7, 9]. The treatment for HACE is 
immediate descent in conjunction with oxygen, if available, and Dexamethasone [8, 10, 
17] 
1.5.4 High altitude pulmonary edema (HAPE) 
Another form of severe altitude illness is HAPE which often occurs together with AMS 
but it can present itself independent of AMS. Similar to HACE, HAPE also often occurs 
in the nighttime and it is also an urgent medical condition. It is the most common cause 




altitudes over 2500m [11, 19]. In some cases, HAPE can develop to HACE due to an 
exacerbation of already critical hypoxia [10]. Hypoxia of high altitude causes 
constrictions of the some of the blood vessels in the lungs, shunting all the blood through 
limited vessels which are not constricted. Due to this, the pressure in these blood vessels 
which are not constricted increases which in turn results in high pressure leak of fluid 
from the blood vessels into the lungs leading to HAPE [10, 20]. Exertion and cold can 
also raise the pulmonary blood pressure and may contribute to either the onset or 
worsening of HAPE. Individuals suffering from HAPE experience extreme fatigue, 
tachypnea, productive cough, drowsiness, and periphral cyanosis [20, 21].  Pneumonia, 
high altitude cough and bronchitis and asthma are possible differential diagnosis for  
HAPE [9]. 
The treatment of choice  is immediate descent, rest and oxygen supply but in the case , 
immediate descent and oxygen supplement are not available, Nifedipinde is a potentially 
important life saving medication [20, 22]. All this can be summarized by saying that 
altitude illness is common problem in high altitude and it can lead to fatal outcomes if 








1.5.5 Pathophysiology of AMS, HAPE and HACE 
 
Figure 2: Proposed Pathophysiological Process of High-Altitude Illness. (Source: High-Altitude Illness: 
Peter H. Hackett, Robert C.Roach) 
 
At high altitude, hypoxia can lead to vasodilatation, increased capillary blood flow, 
increased capillary pressure and leakage of fluid from the cerebral and pulmonary 
microcirculation. So, the ultimate effect in the brain is swelling with edema. The mild 
clinical scenario in this case is AMS with the sever  form of HACE. Similarly, with 




1.6 Risk factors 
Rate of ascent and individual susceptibility are know  to be associated to HAI [7, 9]. 
HAI is much more common at altitudes higher than 2500 meters but it has been 
recognized between 1500 -2500 meters [23]. Previous history of altitude illness and 
permanent low altitude(<900m) residency are also knwn risk factors for HAI [12]. 
Physical fitness has not been shown to be a risk factor but exertion at altitude has been 
documented to be associated with AMS [24]. 
Children and adults are more susceptible than those over 50 years[12, 25] In general, the 
risk of HAI  does not seem to be different in men and women but  few studies have 
shown that incidence of AMS is higher in women [26]. Although, an association between 
AMS and dehydration has been noted [27], it is unclear whether dehydration is an 
independent risk factor for AMS.  Porters, pilgrims and other native populations are also 
vulnerable to altitude illness as studies have shown [28, 29] 
1.7 Epidemiology of high altitude illness 
It has been shown that 47% of trekkers flying to Lukla at altitude of 2840m from 
kathmandu suffered from altitude sickness during the first 24 hours [30]. In the Mount 
Everest region of Nepal, about 50% of trekkers who alk to altitudes higher than 4000 m 
over 5 or more days developed AMS  [30, 31] and about 84% of people who fly directly 
to 3740 m were affected [26]. The incidence of AMS at moderate altitudes(1500m-
3500m) in Northern America was 25% [12].  High-altitude illness is much more likely to 
occur at altitudes higher than 2500 m but presently it has been  recognized at altitudes 
between 1500 m and 2500 m  [23].  
Some studies have shown that  the prevalence of AMSin the Himalaya vary from 43% to 
63% [30] and 9% to 69% in the alps [15]. The incidence of HACE and HAPE is much 




1.8 Obstructive lung disease and airflow limitation 
1.8.1 Background 
Obstructive lung disease including chronic bronchitis, emphysema and asthma are the 
fourth leading cause of death in USA [32].  Environmental air pollution and cigarette 
smoking has been linked to increased prevalence of obstructive lung disease [33]. 
Asthma is most common in children but can  occur in any age group [34]. Chronic 
bronchitis and emphysema can together be called as a single disease entity as COPD 
These lung diseases have a common feature of airflow limitation as measured by the 
Spirometry. Expiratory volume in the first second (FEV1) is low and there is low ratio of 
FEV1 to forced vital capacity (FVC) [35].  
Chronic Obstructive Pulmonary Disease (COPD) is a major cause of morbidity and 
mortality around the world.  Currently, 210 million people worldwide have COPD while 
3 million people died of COPD in 2005.  It has been predicted that COPD will be the 
fourth leading cause of death worldwide by 2030 [36].  
The most common symptoms of COPD are chronic cough and difficulty of breathing, 
initially only on exertion but later also at rest. It is a progressive disease that may lead to 
death. It is most frequently diagnosed in people agd 40 or over.  The most important 
causes of COPD are cigarette smoking, indoor air pollution (biomass fuel used for 
cooking and heating), air pollution, occupational dusts and chemicals vapors, irritants, 
and fumes  [37].  Approximately, 15% of tobacco smokers suffer from COPD [38, 39].   
The diagnosis of airflow limitation is based on spirometry showing a reduced FEV1/FVC 
ratio below 0.7. The seriousness of COPD is then graded based on post-bronchodilator 
FEV1 expressed as percent of predicted value for the individual  [40, 41]. Other tests 
such as pulse oximeter, radiological procedures, arteri l blood gas (ABG), alpha -1-
antitrypsin level are also valuable though non-specific in diagnosis and determination of 
severity of OLD [40]. Table 1 shows the COPD classifications based on Gold criteria 
[42]. 
Prevalence and mortality of obstructive lung diseases in general is high and similarly the 
medical cost associated with them has been increasing in recent years.  Therefore, it is 




costly stages of diseases [43]. Although, COPD and asthma account for most obstructive 
lung diseases, a broad spectrum of other disorders, including bronchiectasis, upper 
airway lesions, bronchiolar diseases, and some interstitial lung diseases, are associated 
with airflow limitation. These less common forms of obstructive lung diseases are often 
misdiagnosed because of their uncommon occurrence and poor recognition [44]. 
 
Table 1: Classification and diagnosis of COPD (GOLD) 
SEVERITY  SPIROMETRY  
COPD definition Post-bronchodilator FEV1/FVC < 0.7 
Mild (GOLD I) FEV1 > 80%predicted 
Moderate (GOLD II) FEV1 50 - 80% predicted 
Severe (GOLD III) FEV1 30 - 50% predicted 
Very Severe (GOLD IV) FEV1 < 30% or  <50% with respiratory failure 
 Source: http://www.goldcopd.com  
WHO estimates that about 1.1 billion people worldwie are smokers which is almost one 
third of the world population [45]. Prevalence of tbacco smoking in Nepal is also very 
high and one survey in rural areas in Kathmandu showed that the prevalence of daily 
tobacco smoking in men was 85% whereas in female was 62% respectively [46]. 
Tobacco smoking has been anecdotally reported to besimilarly prevalent in high altitude 
porters though there are no data specifically in this group of workers.   
The indoor use of biomass fuels increases the risk of airflow limitation and especially in 
the less developed countries and rural areas; it may be the most important contributor for 
the prevalence of COPD [47-50].  The prevalence of COPD in Nepal has been estimated 
at 18.3%  [51] .    
1.9 Rationale of the study 
Working as a porter at high altitude can be a dangerous job. Porters often carry a load 
which is double their own body weight. Human-powered load carrying, in geographical 




study regarding their awareness and incidence of AMS is almost non-existent. It would 
be challenging but very informative to explore this group in regards to their awareness 
and prevalence of AMS. Due to a possible high prevalence of tobacco smoking and the 
use of biomass fuels for indoor cooking among porters, we hypothesize that early 
airways disease may be present in porters working in this region and that they might 
suffer from different forms of obstructive lung disease. Obstructive airway disease may 
also be a risk factor for HAI. Early detection and followed by effective treatment will be 
important for effective control of these conditions. Spirometry is an important diagnostic 
tool for preliminary diagnosis of respiratory diseas. Spirometry data on the porters in 
Everest region is non-existent. Findings of our study will be useful for further planning of 
implementation for preventative initiatives and medical care. It is also of interest to 
ascertain whether working as a high altitude porter is possible for persons with airflow 
limitation and whether such airflow limitation may expose the porter to other high 






CHAPTER 2: OBJECTIVES 
2.1 General objective 
The general objective of the study was to measure awareness and prevalence of high 
altitude illness and obstructive lung disease among porters in Khumbu Valley. 
2.1 Specific objectives 
1. To determine the awareness of acute mountain sickness. 
2. To determine the prevalence of acute mountain sickness at Namche Bazaar and 
after ascent from Namche Bazaar until Everest Base Camp. 
3. To describe the prevalence and burden of tobacco smoking. 
















CHAPTER 3: METHODOLOGY 
3.1 Research design 
Study design was cross-sectional. This study was done between May-July 2008. 
3.2 Study site 
The study was conducted in the Khumbu Valley or Everest Region. It is one of the most 
popular trekking regions in Nepal. Khumbu is one of the three settlements of Sherpas. It 
is located at the Solukhumbu district in north-eastrn area of Nepal. Khumbu elevation 
ranges from 3300m all the way to highest point in the earth, Mount Everest, 8848m.This 
region is famous due to its proximity to some of the worlds’ highest mountains and home 
of Sherpas-the famed mountain people of Nepal. 
Namche Bazaar is small village in this region situated at an altitude of 3460 metres. It is 
well- known among tourists trekking in the Khumbu region and especially with the 
mountaineers. The main income of people living in Namche is tourism and has 
population mainly of Sherpa. It takes two days from the nearest airport located at Lukla 
to reach Namche on foot. Travellers usually spent one night in Phakding (2610m) or 
Monjo (2835m) for acclimatization where in Namche travellers usually spend 24-48 
hours for acclimatization. Moving up in the Khumbu valley, one will find several small 
villages including Deboche (3710m), Pangboche (3930m),Tengboche (3860m), Pheriche 
(4270m), Dingboche (4410m), Gorakshep (5140m) before reaching the Everest Base 
Camp which is situated at 5364m. 
 








3.3 Study population 
We included porters working in this region at or above Namche regardless of ethnic 
background during May to June 2008. The porters were classified in two groups. One 
group was working independently and next group was orking with expeditions or 
foreign trekkers. They were enrolled by the primary investigator (author) en route 
directly on place of study i.e. Namche and above until Everest base camp at different 
altitudes. This study was done with bases in Namche Bazaar (3460m), Pheriche (4270m), 
Thokla Pass (4830m), Gorakshep (5140m) and Everest Base Camp (5364m). 
A. Inclusion criteria  
We included porters 18-65 yrs of age either male or female working independently or for 
expeditions. 
B. Exclusion criteria 
• Pregnant females (missing menstruation for more than 7 days).  
• Porters who have spent in study site at least for 2days or 48 hours as they will be 
acclimatized already.  
• Porters who were descending. 
 3.4 Sampling  
The prevalence rate of 50% was used as reference for sample size calculation on the basis 
that no study has been done on this topic previously including all ethnic groups of 
porters. This prevalence rate was used as reference to alculate sample size with 5% 
absolute precision and 95% confidence interval. Theminimum required sample size (n) 
was 384 (using Open-Epi version 2.2, CDC, USA). Due to time constraints and financial 
limitations, we were only able to include 200 porters in the study. Every case was 
enrolled by the administrator (author) directly. 
3.5 Study procedure   
The study was performed in five different villages in Khumbu valley located at different 




(4270m), 14 in Thokla Pass (4830m), 4 in Gorakshep (5140m) and 7 in Everest Base 
Camp (5364m) were interviewed and examined. AMS scoring system (Lake Louis score) 
was used to diagnose AMS. This scoring system is baed on Lake Louis AMS 
questionnaire (see appendix 3). Spirometry was performed on 160 porters in Namche 
Bazaar (3460m).  
3.5.1 Physical examination  
This was performed by researcher and research assistant  after enrolling the participants 
in the study. There were four research assistants who were all physicians and members of 
Mountain Medical Society of Nepal (MMSN). Vital signs (BP, HR, and RR) were taken 
and recorded after each porter has 15 to 20 minutes rest. The vital signs were taken in 
sitting position. Oxygen saturation was taken by using Pulse Oximeter.  Finger oximeter 
from Smiths Medical Family Companies was used. The product described is covered U.S 
Patent No.6, 654,621.  The 3rd or 4th digit finger was used to record the oxygen 
saturation because of thinner fingernail to have the better pulse signal.  
3.5.2 Lake Louis score (LLS) 
Lake Louis score was used to diagnose AMS [53].  
Diagnosis of AMS was based on: 
• Rise in altitude within the last 4 days 
• Presence of a headache 
Plus 
• Presence of at least two other signs and symptoms such as nausea, fattigue and 
difficulty of sleeping. 
Total score of 3 or more. 
Total score of 3 to 5 was defined as “mild AMS” and a score of 6 or more as “severe 
AMS”. Lake Louis questionnaire was made available in native Nepali Language (see 





3.5.3 Interview schedule   
A standardized close-ended questionnaire was administered for interviewing the porters 
for socio-demographic information, awareness of AMS and informations on smoking 
history and respiratory symptoms (see appendix 1). Questionnaires were first developed 
in English language and translated to native Nepali language by the researcher. The 
questionnaires for measuring awareness of AMS were modified from a previous study 
‘Awareness of altitude sickness among a sample of trekkers in Nepal’ by Dr. James 
Glazer [13]. Questions were designed to attain their knowledge of acute mountain 
sickness. An altitude awareness score was established with a maximum score at 10 
points. Questions included mainly signs and symptoms, cause, treatment and prevention 
related to acute mountain sickness. In an effort to know their previous altitude exposure 
and acclimatization history, subjects were asked about their place of residence, the 
number of times they have been to Namche and above until Everest Base Camp. The 
questionnaire used for interviewing about previous medical history and respiratory 
symptoms was a modified version of the British medical research council questionnaire. 
Porters were asked about history of cough, breathlessness, wheezing, past medical 
history, and smoking habits.  
3.5.4 Spirometry 
Spirometry was done in Namche. Procedure for spirometry was attempted according to 
ATS/ERS standards for pulmonary function testing. The primary investigator was trained 
to perform spirometry before leaving for the field. All porters were instructed by 
researcher for proper blowing as fast, hard and long as possible with at least three tests in 
the seated position. Those who completed at least one acceptable FEV1 and FVC 
measurement (lasting at least 6 seconds) were chosen f r further analyses. Spirometry 
was not done in porters who denied to do it and whofelt dizzy after doing the first trial. 
Denial was mainly due to use of spirometry for the first time in most of the individuals 
and being new to them. Individuals were afraid due to fear of adverse effect which might 
lead to acute mountain sickness. This belief was more frequent among porters after 
Namche as altitude increased. Individual decisions were respected and they were not 
coerced to perform the test. Above Namche, mostly due to denial and extreme weather 
conditions, spirometry was not performed. The test measures for various pulmonary 




Norway for analysis. Reference values for spirometry for lung volumes were used as 
10% less than caucasians [54, 55].  
Airflow limitation in our study was defined as FEV1/FVC<0.7 [40]. 
3.6 Data processing and analyzing 
All data obtained from interviews and physical examinations was checked for 
completeness and consistency and reviewed by the researcher. SPSS 15.0 was used for 
data entry and analysis. Double data entry was done. Two data sets obtained from data 
entry were validated by the researcher. Basic descriptive statistics including measure of 
central tendency, variance and frequency were computed for all important variables 
measured in the study samples. Chi-square test was used for analyzing association in 
categorical data, and t-test was used for analyzing comparisons of group mean. The level 
of significance was set at 5% and interpretation was done accordingly. 
3.7 Ethical clearance 
Ethical clearance was obtained from Nepal Health Research Council (NHRC) in Nepal.  
Informed consent was taken from each participant before enrolling them in the study. 
Mainly, the oral consent was taken. The nature of the study, possible harms and benefits, 
rights of participants and duties of the researchers were informed to each participant. 
Participants were ensured to maintain the confidentality. Participation was voluntary and 
participants had right to withdraw from the study at any time without any adverse 








CHAPTER 4: RESULTS 
4.1 General characteristics of participants 






Age group 18-29 105 52.5 
 30-39 years 55 27.5 
 >40 years 40 20.0 
Sex Male 199 99.5 
 Female 1 0.5 
Marital status Single 59 29.5 
 Married 141 70.5 
Education Illiterate 108 54.0 
 Literate 92 46.0 
Alcohol consumption Daily 136 68.0 
 Occasional 7 03.5 
 Total abstainers 57 28.5 
Smoke (Tobacco) Smokers 65 32.5 
 Ex-smokers 7 03.5 
 Non-smokers 128 64.0 
Chewing Tobacco Yes 66 33.0 
 No 134 67.0 
Working Independently 169 84.5 
 Expeditions 31 15.5 
 
Table 2 shows demographic and characteristics of participants of this study. A total of 
200 porters were interviewed and examined. With regards to obstructive lung disease, 
200 were interviewed and examined, 160 were asked to perform spirometry and of these, 
4 refused. Among the 200 interviewed, 199(99.5%) were male and 1(0.5%) female. The 




Most of the porters (54%) were illiterate. Illiterate group included those porters who have 
never been to school and literate group were those who had primary and above education. 
Almost 32.5% were current smokers, 3.5% were ex-smokers. Almost 68% consumed 
alcohol daily [2.25units (1 unit = 1 glass of homemade Rakshi or rice wine)] whereas 
66% used chewing tobacco. In our study, 169(84.5%) of porters were working 
independently and 31(15.5%) were working in expeditions during the time we did our 
study. However, 24(12%) porters who were working independently during our study had 
experienced once or more working with expeditions previously and similarly, 5(2.5%) 
porters who were working in expeditions had worked independently. 
 4.2 Working as a porter: socio-economic aspects  
Table 3: Working as a porter: socio-economic aspects 
N=200 Yes Percentage (%) 
Paid-well 161 80.2 
Good income 160 80.5 
Risky job 119 59.8 
Will continue working as porter 51 25.6 
Knowledge of porters organizations 46 23.0 
Organizations assistant in awareness 38 19.1 
Satisfied with  work 175 87.5 
 
Table 3 shows porters’ personal experiences with work and socio-economic aspects 
related to their job. About, 80% of total studied porters said they are paid well and 
income from working was enough to survive though 119(59.5%) of porters thought that 
the job was risky because of AMS and the other life thr atening conditions. Only 26% 
will continue working as porters, making it as their profession. About 23% of porters had 
the knowledge of different porter organizations established in the region and 19.1%, said 
they were given different awareness programme regarding AMS. The majority of porters 




4.3 Source of information regarding AMS                                                                                  
Figure 3 shows the source of information porters had regarding AMS. They came to 
know about AMS mostly from their friends working with them (94.3%) and self 
experienced of AMS (15.4%) was the major source of inf rmation and internet being the 
least source (1%). Almost 50% of the porters had the previous history self-reported 
AMS. The mean altitude where they had AMS was 4839m. We were not able to get the 
previous history of HAPE and HACE.   Most porters [136 (68%)] said that there are 
enough health posts (number were not specified) on route from Namche to base camp but 
only about 23.5% believed there is easy access to AMS medications. A minority of 
porters (26 [13%]) were carrying medications during terview. Out of them, 12 were 
carrying Diamox, 15 were carrying Anti-inflammatory drugs and 1(3.84%) was carrying 
Antibiotic. Only 11(5.5%) porters, all working on different expedition teams had 









Fig 3: Source of Information regarding AMS 
 Multiple response questions sum not equal to 100% 
 
Furthermore, 173(86.5%) of porters wanted to know more about AMS and its 




group. Almost, 75% of porters thought health professionals are the best source for getting 
more informative guidance and counseling regarding AMS whereas only 5% thought 
internet might be the good way for AMS awareness programme. 
4.4 Acute mountain sickness awareness score  
Table 4: Number of porters answering correctly for each individual component of 





A. Symptoms of AMS   
1.  Headache 163 81.5 
2.  Nausea 98 49.5 
3.  Dizziness 75 37.5 
4.  Fattigue 70 35.0  
B. Causes of AMS   
5.  Altitude 100 50.0 
6.  Ascent rate 129 64.5 
C. Other factors   
7.  Prevention 139 69.5 
8.  Treatment 178 89.0 
9.  Life-Threatening 164 82.0 
10. Partner with AMS* 41 20.5 
*Porters who answer correctly to take a break and stay at same place until AMS symptoms pass 
away in case their friends will have AMS 
Table 4 shows the scoring of the study population on the individual items in the AMS 
awareness score. Almost 82% of the porters believed that the headache was one of the 
main symptoms of AMS whereas only 49.5% of porters hought nausea was also caused 
by AMS. About, 37.5% of porters believed that dizziness was a symptom of AMS 
whereas only 35% answered fatigue as a symptom of AMS. 
Regarding the cause of AMS, 50% believed altitude causes AMS and 64.5% answered 




About, 69.5% of porters answered correctly for the possible preventive measures in AMS 
and 89% believed there is treatment for AMS whereas 82% answered AMS as a life 
threatening condition. Only 20.5% of porters answered correctly for the measures to take 
for the treatment of partner with AMS. 
4.5 AMS awareness categorization 
Highest scoring was 10 and lowest being 0. The score  were normally distributed with 
mean score at 5.09 and standard deviation of 2.25 (Figure 4). 
 
Fig 4: AMS Awareness score for individual porters (n=200) 




Low (0-4) 72 36 
Middle (5-7) 100 50 
High (8-10) 28 14 
Table 5 shows the categorization of porters in three groups according to awareness score. 
Those porters who achieved awareness score eight and above were categorized in highly 
aware and 28(14%) were in this group. Porters who scored 5 - 7 were categorized in the 




scored less than 5 were categorized in group having low knowledge. Number of porters 
who were categorized to have low knowledge was 72(36%).  
4.6 Comparison of some porters characteristics with AMS awareness 
score  










n (%) p-value* 
Education     
Uneducated 46 (42.6) 54 (50.0) 8 (7.4) <0.05 
Educated 26 (28.3) 46 (50.0) 18 (21.7)  
Age     
18-39 years 58 (36.3) 76 (47.5) 26 (16.3) 0.14 
40 and above 14 (35.0) 24 (60.0) 2 (5.0)  
Experience     
0-5 years 40 (41.2) 43 (44.3) 14 (14.3) 0.75 
6-10 years 14 (35.0) 20 (50.0) 6 (21.4)  
11-20 years 14 (29.1) 28 (58.3) 6 (12.5)  
21 years and above 4 (26.6) 9 (60.0) 2 (13.3)  
History of AMS     
AMS (+) 22 (22.0) 56 (56.0) 22 (22.0) <0.001 
AMS (-) 50 (50.0) 44 (44.0) 6 (6.0)  
Working     
Independently 63 (37.5) 90 (53.3) 16   (9.5) <0.001 
Expeditions 9 (29.0) 10 (32.3) 12 (38.7)  
*p-value of chi square 
Table 6 shows that Self –reported previous history of AMS and working type were 
significantly associated with altitude awareness score (p<0.001).  Education was also 
found to be statistically significant predictor of AMS awareness, with educated group 
having more altitude awareness score (p<0.05).  Theport r’s age and years of experience 




4.7 Prevalence of acute mountain sickness 
We interviewed and examined 160 porters in Namche Bazaar (3460m), 15 in Pheriche 
(4270m), 14 in Thokla Pass (4830m), 4 in Gorakshep (5140m) and 7 in Everest Base 
Camp (5364m).  
Table 7: AMS case describing personal history(age in years, sex and smoking 
status), location/altitude in meters, ascent profile for previous 24 hours 




















84 101 28 130 70 7 




88 106 24 120 80 6 




84 112 20 130 90 6 





88 113 24 120 90 7 





82 116 23 110 80 6 





84 102 22 130 90 8 
7 19,Mns EBC (5364) Lobuche-EBC 
(500) 
86 108 20 130 70 8 
8* 38,Ms EBC (5364) Gorakshep-
EBC  (200) 
83 114 22 130 80 10 
* With previous history of AMS 
    3 to 5 = mild AMS 
    6 or more = severe AMS 
   Abbreviations (Ms-male smokers, Mns-Male non-smokers, EBC-Everest Base Camp) 
Table 7 shows prevalence of AMS. The cases were found at different altitudes between 
Namche and base camp. Eight out of 200 porters werediagnosed to have AMS using 




21.4% at 4830m and 28.5% at 5364m. All porters in our study who had AMS were 
classified as having severe AMS and the mean altitude where they suffered from AMS 
was 4769.7m. Six of the eight porters who had AMS were smokers. Prevalence among 
current smokers was 9.2%. Six of the porters had self reported history of AMS. Self 
reported previous history of AMS was at a mean altitude of 4375m. Seven of them were 
working individually and one was working for expeditions. Most of them were heading 
to Everest Base camp and they planned to reach the Bas Camp within 2-3 days (48-72 
hours) from Namche Bazaar. None of them were taking Diamox.   
Table 8: Demographics and vital signs in porters with AMS compared to porters 
without AMS  
AMS (n=200) Yes (n=8)  mean 
(SD) 
No (n=192)  mean 
(SD) p-value* 
Systolic BP 125.0   (7.5) 108.2 (12.2) <0.001 
Diastolic BP 81.2   (8.3) 74.2 (10.8) 0.50 
Pulse rate 109.0   (5.6) 79.4 (12.1) <0.001 
Respiratory rate 22.8   (2.5) 18.0   (3.1) <0.01 
SpO2 84.8   (2.2) 92.4   (3.5) <0.001 
BMI 21.1   (0.9) 21.3   (1.6) 0.75 
Age 30.0 (10.3) 29.1   (9.6) 0.70 
*p-value: Significance of Age, BMI and vital signs tested with independent sample t-test 
Table 8 shows the difference of vital signs in the context of mean and standard deviation 
between AMS and non-AMS cases. Similarly, Age and BMI were also compared 
between two groups. Both systolic and diastolic blood pressure was higher in porters 
with AMS.  There was also significant difference in mean of respiratory rate, pulse rate 
in porters with AMS which was higher than the group without AMS. Systolic BP, pulse 





4.8 Presenting airways symptoms 





n =72 (%) 
Non- smokers 
n =128 (%) 
Total   
n (%) 
p-value* 
Cough in morning 46 (63.9) 73 (57.0) 119 (59.5) 0.34 
Cough during the day 31 (55.4) 25 (44.6) 56 (28.0) <0.001 
Phlegm 40 (55.6) 40 (31.3) 80 (40.0) <0.01 
Cough for > 3 months during 
a year 
23 (31.9) 11 (8.6) 34 (17.0) <0.001 
Cough >3 weeks  in 2 years 22 (30.6) 20 (15.6) 42 (21.0) <0.05 
Breathlessness than own age 29 (40.3) 30 (23.4) 59 (29.5) <0.05 
Breathlessness climbing two 
stairs at ordinary pace 
18 (25.0) 16 (12.5) 34 (17.0) <0.05 
Breathlessness at normal 
pace at level ground 
4 (5.6) 4 (3.1) 8 (4.0) 0.40 
Breathlessness while at rest 0 (0.0) 1 (0.8) 1 (0.5) 0.45 
Attack of breathlessness 21 (29.2) 12 (9.4) 33 (16.5) <0.001 
Wheezing sound ever 21 (29.2) 15 (11.7) 36 (18.0) <0.01 
*p-value o of chi-square 
Table 9 compares the airways symptoms between smokers and never smokers. Coughing, 
coughing with phlegm, cough for 3 months or more during a year, cough with cold more 
than 3 weeks in 2 years, breathlessness than own age, breathlessness at normal pace, 
experiencing attack of breathlessness and wheezing sound were all significantly more 
frequent among smokers.  Particularly, it should be noted that “attacks of breathlessness” 
were almost 3 times more frequent in porters who smke. Morning cough (also called 
“Khumbu cough”) frequency did not vary significantly by smoking status and is in 













FEV1 2.92 (0.8) 2.94 (0.5) 0.82 
PPFEV1 93.59 (22.9) 93.32 (15.8) 0.94 
FVC max 3.79 (1.0) 3.82 (0.6) 0.87 
PPFVC 100.81 (23.0) 100.77 (16.0) 0.99 
FEV1/FVC 0.77 (0.09) 0.77 (0.08) 0.87 
Frequency of air flow 
limitation n [(%)] 
8 (19.15%) 14 (17.07%) 0.73** 
Frequency of airflow limitation defined as FEV1/FVC<0.7 
p-value of independent sample t-test and chi-square**  
Table 10 shows pulmonary function test results for the 123 smokers and non-smokers 
who were able to perform at least one acceptable FVC maneuver.  FEV1/FVC ratio was 
similar in both groups with a mean at 0.77 (SD 0.08).  Similarly, there was no significant 
difference in PPFEV1and PPFVC in two groups. Total of 8(19.15%) in current/ex-
smokers and 14(17.07%) in never smokers group have FEV1/FVC < 0.7. Smoking does 
not seem to be associated with airflow limitation in this group of porters. 
4.10 Physical examination 
In the examination of chest, wheezing/rhonchi was present in 23(11.5%), and 
crepitations/rales was present in 3(1.5%).Three of the AMS cases had wheezing and one 
presented with rales. HAPE was ruled out in the porter who presented with rales. On 
examinations of abdomen, water brush and symptoms of acute peptic ulcer disease was 
present in 29(14.5%) of porters. Five (2.5%) porters had edema on bilateral leg and 





 CHAPTER 5: DISCUSSION 
The overall prevalence of AMS was 4%. Similarly, 50% of porters were categorized in 
the middle range regarding awareness of AMS. The prevalence of current/ex-smokers 
was 36% and the prevalence of airflow limitation was 17.8%. 
5.1 Methodological issues 
This study was designed as a cross-sectional survey. A cross-sectional study has the 
advantage of being economical, as well as easy to carry out. With limited resources and 
time periods, it was the most useful study design for our research questions. Similarly, it 
was best suited for prevalence study.  
Our study sample was based on convenience and as such, selection bias can be one of the 
potential biases in our study. During the study period, we were able to include almost all 
porters passing through at the time.  With the exception of 3 porters less than 18 years 
old, who were not included due to falling outside inclusion criteria for age, there were no 
porters who refused. Next, we included the porters who were heading towards Base 
camp, so porters who were descending, possibly due to AMS, were not included in the 
study.  
Despite having a high response rate, there is unquestionably a selection bias due to 
healthy worker’s effect. This bias may underestimate the frequency of porters with 
respiratory problems or weaker health because they tend to leave the work. A healthy 
worker effect is a nearly unavoidable source of bias in occupational health studies though 
a longitudinal study design attenuates the effect.  Thus, in the case of our study, using a 
longitudinal design and recruiting porters just as they begin their career and following 
them during their first trips, would be close to an ideal method for our research question.   
Recall bias could also have influenced the results because past medical history regarding 
AMS was recorded during the study. Some of the porters may have wished to hide their 
previous medical history and other daily habits like smoking and drinking alcohol. This 




We used interview-based questionnaires to test their level of awareness regarding AMS 
and to reveal their past medical history mainly rega ding respiratory symptoms. It is very 
important to interpret the questions correctly. We p rformed pre-testing of the 
questionnaire in few porters and changes were made in the final version before collecting 
the data.  Ideally, questionnaires should be filled out by the subject themselves to avoid 
interviewer-added bias.  Because of high prevalence of illiteracy this was not possible in 
our study. 
5.2 External validity 
This was the first study targeted to porters in the Khumbu region regarding level of 
awareness of AMS and prevalence of tobacco smoking and respiratory symptoms. This 
study can be a reference for future epidemiological studies targeting this group for 
awareness of mountain sickness and obstructive airways diseases. The study was 
conducted in Khumbu valley. This is one of the most famous trekking destinations 
among tourist in Nepal. This is the gateway to Mount Everest, the highest peak in the 
world. The numbers of porters in this region may well b  more than the other tourist 
destinations of Nepal like in Round Annapurna. Most f the porters were not ethnic 
Sherpa but different ethnic groups from lowland. This being the case, one could argue 
that the Khumbu is the ideal setting for investigating porter’s health and working 
conditions in general. 
5.3 Awareness of AMS 
Knowledge among 50% of porters was in the middle range, 36% had low knowledge of 
AMS, and only 28% were in higher knowledge group. Questions related to AMS signs 
and symptoms, treatment, causes and prevention wereincluded during interview. 
Previous study done on trekkers in the Annapurna region in Nepal showed that awareness 
among tourist population was also in the middle range [13]. This study among tourist 
also showed that there was an association between experi nce and knowledge (awareness 
increased with experience of being in high altitude in years) in contrast to our study.   
A previous study reported that porters in Nepal carry luggage almost double their weight 




exertion has been identified as one of the major risk factor for developing AMS [10, 57]. 
So, porters who have less knowledge have more chances of getting AMS. 
Most of the porters (86.5%) showed interest to know more about AMS where physicians 
was thought to be the most useful source (74.5%), and internet being the least (10%) 
which is in contrast to the study among foreign trekkers where internet was one of the 
major source of information [13] .Most porters had learnt about AMS through their 
friends (94.3%) or  from self experienced (15.7%).   
Belief in herbal medicine was prominent. We found that 37.5% of porters believe that 
herbal medicine can cure AMS, though still 73% will prefer to take western medicine in 
case they suffered from AMS. There are different herbal treatments which are 
traditionally used for prevention of AMS but Ginkgo biloba is the one studied most. In 
one study, Ginkgo biloba prevented AMS incidence for m derate altitude (5400m) with a 
gradual exposure. A total of 44 western climbers were r cruited and randomized into two 
groups. Climbers who were given Ginkgo biloba did not develop mountain sickness 
whereas in the placebo group 40.9% developed AMS [58]. In a controlled trial it was 
found to be effective in reducing both the symptoms and the incidence by almost 50% 
during an abrupt ascent to 4100m [59] . But in contrast, the study done in 2004 by 
Gerstch et.al revealed no preventive action of Ginkgo biloba but instead suggested that 
acetazolamide 250mg twice daily had prevented sympto s of AMS [60]. There are no 
other documented studies on herbal preparations which can be used in prevention and 
treatment of AMS. Presently, it has been in practice for sojourners in Nepali Himalayas 
to be prescribed or advised 125 mg of acetazolamide twic  daily [61]. 
Another interesting finding is that 36% of porters thought the cause of AMS was 
vegetation. It is the belief among them that some plants or grasses in high altitude cause 
AMS. High altitude plants like Sunpati (Rhododendron anthopogon D. Don) were 
thought to be one of the risk factors. These plants were more commonly found in altitude 
above 4000m. Porters had belief that smell of Sunpati can cause AMS. One of our 
research assistants complained of strong bad smell which was of Sunpati before 
presenting with symptoms of AMS between Dingboche (4410m) and Dugla Thokla 




Most porters seem to be unaware of what to do in case their partner or friends had AMS 
as 69% said that they would go to less altitude as soon as possible and 82% had a belief 
that AMS is life-threatening.  The more appropriate ction might include simply rest, 
fluid and drinks are the first way of treatment, as it i  most often not necessary to move 
down altitude at once. AMS is in itself not life-threatening. These responses show that 
low awareness might lead to misinterpretation of the problem. 
A 12-year follow up study in Annapurna region suggested that increased in awareness 
was one of the main reasons for decreased prevalence in AMS. The study  found an 
increase in awareness  in trekkers from 80% to 95% with decrease in AMS prevalence 
from 43% to 29% [62].  That study also found medication usage among those trekkers 
increased from 17% to 56%; mainly acetazolamide and algesics [62]. In our study, 
only 13% of porters were carrying similar medications.  
Another study done among trekkers climbing Thorang Pass (5400m) showed, 80% had 
elementary knowledge of the diagnosis and treatment of AMS.  Elementary knowledge 
was defined to be having knowledge of at least 2 symptoms of AMS and a treatment 
where descent was thought to be the most important.  The study reported that 3% of 
studied population had never heard of AMS before [63].  In our study, 6% of porters 
have never heard of AMS.  
It was common for porters to work two or three times a week from Lukla to Namche 
round-trip. About 29% of porters in our study never have been to base camp. Apparently, 
we did not find any relation between numbers of times porters reaching Namche Bazaar 
and Base Camp to the level of awareness regarding AMS.  
A minority of the porters (23%) have knowledge about different organizations working 
for their welfare. The majority of porters (80.5%) was satisfied with their work and 
payment and will continue to work as a porter although they think their job is risky.  
5.4 Prevalence of AMS 
We found 8 (4%) porters with AMS, diagnosed according to the Lake Louis 
questionnaire. All 8 porters developed AMS at different altitudes. We interviewed and 




Pass (4830m), 4 in Gorakshep (5140m) and 7 in Everest Base camp (5364m). In these 
places where we interviewed and examined the porters, we established small camps. One 
AMS case was found in Namche, 2 in Pheriche, 3 in Thokla Pass and 2 in Base Camp. 
The prevalence of AMS was 0.6% at 3460m, 13.3% at 4270m, 21.4% at 4830m and 
28.5% at 5364m.  
A study performed in the Swiss Alps on 466 climbers also found increasing prevalence 
of AMS with increase in altitude: 9% at 2850m, 13% at 3050m, 34% at 3650m and 53% 
at 4559m.  This study also found the prevalence of HAPE and  HACE to be 2.36% at an 
altitude of 4559m  [15].  
Hackette and Rennie found among 278 trekkers on way to Everest at altitude of 4200m 
an overall prevalence of 53%.  Two years later they found decrease in prevalence to 43% 
in 200 trekkers which is still much higher than our study for similar altitudes  [31].   In a 
study done in Nepal among pilgrims in Gosaikunda at 4154m, the incidence was 4.4 % 
[64] but the next study done on the same site but at altitude of 4300m  after few years 
showed increased incidence of AMS to 68% [29] . These were grossly conflicting results 
probably due to different methods of diagnosis nevertheless they were some of the few 
studies done on native Nepali pilgrims. 
AMS cases were diagnosed more frequently as we ascended. There are basic and fixed 
timetables recommended for trekkers heading for Base Camp, and these are also applied 
for most of the porters working in expeditions.  However, for those working individually, 
recommendations are often ignored and they increase their altitude haphazardly with 
large elevation gains per day. It is usually up to them to decide how long they can walk in 
a day. During our study, 7 porters who had AMS were trying to reach the Base camp 
within two to three days (48-72hours) from Namche because of the high demand of 
porters to Base Camp. They were trying to ascend almost 2000m in 48-72 hours where it 
is preferably advised to take 4-5 days to reach base camp from Namche Bazaar. 
Advisable ascent rate to avoid AMS would be 300m per day above 2000m  [65]. A study 
in Kilimanjaro in Tanzania among Finnish trekkers documented 75% incidence of AMS  
and was contributed to rapid ascent [14]. In our stdy, it would be reasonable to argue 
that rapid ascent encouraged by a high porter demand is an important factor in 




In our study, 50% of the study population had self reported previous history of AMS with 
a mean altitude of 4839m and lowest reported altitude of 3860m which is much higher 
than altitudes reported in studies of western population where AMS has been reported at 
altitudes as low as 1500m  [66]. 
Among trekkers climbing in Thorang Pass (5400m), the overall prevalence of AMS was 
found to be 63 % and AMS was positively correlated with rate of ascent and negatively 
correlated with pre-trek acclimatization [63]. Since, trekkers and climbers are staying 
about two days in Namche Bazaar for acclimatization, the porters working with them also 
stay back and our findings of only one porter with AMS working in expeditions might be 
due to this fact that porters working in expeditions are more acclimatized.  
Body mass index has previously shown correlation with AMS in men [63]. But contrast 
to this study, we did not find any correlation betwen BMI, age and alcohol consumption 
and AMS in our study.  There was an association betwe n smoking and AMS for 
unknown reason. Prevalence of AMS among current-smokers was 9.2%. Six of eight 
porters with AMS were smokers.   
There was no relation between those who had self report d previous history of AMS and 
present outcome of AMS. Apparently, we did not find any relation between AMS 
outcome and the numbers of times porters previously had been to Namche Bazaar or 
Base Camp. 
We found that there was no significance difference between the two groups regarding the 
diastolic blood pressure but systolic blood pressure was found to be higher in AMS 
group. This was in contrast to the study done in the Swiss Alps which concluded that the 
cardiovascular system is not primarily affected in acute mountain sickness, though they 
had similar findings regarding pulse rate and respiratory rate which was found to be 
higher on AMS group [15].  
Oxygen saturation decreased according to increased in altitude. In AMS group, mean 
Sp02 was well below than that of non-AMS group. Decrease saturation pressure might be 
a specific indicator of inadequate acclimatization and impending AMS [67]. In our study, 
mean oxygen saturation among porters with AMS was 84.8% compared to non-AMS 




During our study, we advised those with AMS not to ascent further and stay in the 
nearest village or, alternatively, to stay with us until the symptoms pass away. Some of 
them were even asked to descend to nearby village due to weather conditions. We 
furthermore provided them with acetazolamide 125mg and paracetamol 500 mg. 
acetazolamide has proven to be effective in prevention of AMS as well as it has some 
efficacy for the AMS cases [61]. One porter presented with rales but apparently he did 
not develop any complications related to HAPE. We were not able to follow up porters 
with AMS further in the next day though there were no reports about any casualties 
during the period. 
The prevalence of AMS among porters in Khumbu is not as high as in tourist or trekkers 
or pilgrimage in other parts of Nepali Himalayas but it must not be underestimated. This 
population is not immune to AMS as other sojourners to Himalayas. 
5.5 Prevalence of smoking and airflow limitation in high altitude 
porters           
In our study, we found that prevalence of current tobacco smoking was 34% whereas 2% 
of the porters were ex-smokers. Among ever-smokers, the median number of pack years 
was 1.7 (mean 3.7). Low pack year of smoking can be due to young age of porters and 
usually they smoke few sticks per day. The average number of cigarettes smoked was 6 
sticks per day and the average number of years they have smoked was 13 years.  We 
were able to document the prevalence of airflow limitation to be 18% based on pre-
bronchodilator spirometry. The airflow limitation with FEV1/FVC less than 0.7 was seen 
in 8(19%) of porters who were current/ex-smokers and 14(17%) of porters who were not 
smoking. Our findings are in agreement with previous research in Nepal  where the 
prevalence of COPD has been estimated to be 18.3% based on a study in residents who 
were more than 20 years in  two rural communities in a hilly region of Nepal [51] .  
 Airflow limitation in our study does not seem to be associated with tobacco smoking 
(OR 0.849, 95% CI 0.324-2.225). The airway obstruction may be related to smoke from 
open indoor fires or possibly to hyperactive airways nd asthma which are very active in 
young population and shows similar obstructive patterns as in of COPD. During the 
study period, none of the porters reported that they had asthma. The obstruction pattern 




as there is no electrical or gas oven [68]. A study performed in 60 villagers from two 
villages of the Khumbu, Dingboche and Thame, found evidence of early airway 
obstruction defined as reduced forced expiratory flow at 25 to 75% of vital capacity.  
Subjects in the study were young (8 – 45 years) and otherwise healthy though most had 
significant exposure to indoor biomass smoke [68] . 
There is conflicting evidence regarding an association between altitude and COPD 
prevalence.  A study done in Columbia showed the positive relationship between COPD 
prevalence and altitude where as the PLATINO study which was done in five Latin 
American cities which showed negative association with altitude [69, 70].  It has been 
reported in a study that lower air density at higher altitude might alter pulmonary 
function [71]. It was found that FVC was slightly lower and FEV1 was slightly higher 
which would have the net effect of increasing the FEV1/FVC ratio and apparently 
lowering the rate of airflow limitation [71, 72] 
Also in regards to asthma prevalence results are confli ting. One study suggests that 
asthma rates are lower at higher altitude [73] and it is recognized that exposure to cold, 
high altitude air can provoke bronchial irritation leading to obstructive patterns in 
airways [74]. However, mountain environment provides r duced pollutant and vegetation 
(allergens) and thus may be  less likely to provoke hyperactive airways or asthma [75].  
Morning cough was prevalent in 60% of porters and cough during the day was prevalent 
in 56% of porters. Most of the porters were complaining of dry cough. At high altitude, a 
dry, irritating cough is very common and often called the “Khumbu cough” or “Khumbu 
Hack.”  It has been attributed to the inspiration of the cold, dry air which characterizes 
the high altitude environment [76, 77]. There have not been many studies done regarding 
cough at high altitude. The pathophysiology of cough at high altitude is that increased 
minute ventilation of cold dry air at very high altitude is likely to cause airway irritation 
through airway drying, mucus production, post nasal drip from vasomotor rhinitis and 
bronchospasm. The cough is exacerbated further at extreme altitudes above 5500m, and 
may result in intercoastal muscles strain and sometimes even rib fractures [76]. The 
present investigator group experienced the “Khumbu co gh” from Namche and upward 
which was exacerbated as we ascended further up the khumbu valley, and was self-




We found that 21% of porters were giving the history f chronic bronchitis based on 
history of cough for more than 3 weeks in two years in a row. This could be correlated to 
chronic obstructive pulmonary disease as patient history of chronic cough and 
breathlessness is clinical mode of diagnosis of COPD [78].  It may also be simply an 
expression of the “Khumbu Cough.” Thus, the role of altitude in the development of 
OPD and subsequent outcomes is an area that could benefit from further investigations. 
In our study, porters who smoked showed higher a prevalence of respiratory symptoms 
than never-smokers. Attack of breathlessness was almost three times more frequent in 
porters who smoked. It has been reported that breathlessness has been common to those 
who have been smoking for many years and in older ag  group [79]. Further, it has been 
documented in a study done on Norwegian population hat respiratory symptoms 
increased by smoking burden. Almost 12% of the total s udy population reported 
episodes of wheezing or breathlessness during past 12 months. The mean number of pack 
years of smoking was 15.9 and 10.3 among men and women which was much higher 
than in our study [80]. Our study suggested that although most of porters who were 









CHAPTER 6: STRENGTHS AND LIMITATIONS  
This is the first study done in porters in Khumbu region. The results from our study can 
be used a as reference and starting point for future study. 
We used a questionnaire for data collection, so there are chances for misinterpretation of 
the questions by the porters and also by interviewers. This fact means that it is usually 
better to use a self answered questionnaires. We could not able to do it because of high 
illiteracy rate. 
We attempted to do the spirometry according to ATS/ERS criteria but we were not able 
to do acceptable FEV1 and FVC maneuver for all 160 porters. Only 123 porters were 
able to do at least one FEV1 and FVC maneuver. The quality of data was not optimal but 
we were able to get rough impression of airflow limitation. The reasons that we were not 
able to get good quality were due to time burden, location as well as embarrassments of 
porters to do spirometry infront of other participants. In future, more time should be 
given for doing spirometry.  
Our sample was less than calculated sample size. Du to time constraints and financial 
limitation, we were only able to take 200 porters in the study. The actual numbers of 
porters working in that region was not exactly know although we were told by local 
residents the number of porters might be around 400-500 working all through the year 
The political scenario of the country was also a limitation for our study although in the 
region we did our study, the presence of Maoists wanot felt or seen. However, the 








CHAPTER 7: CONCLUSIONS AND REMARKS 
In this study, 200 porters in the Khumbu region were interviewed and examined to assess 
the level of awareness and prevalence of acute mountain sickness and airflow limitation. 
Similarly, spirometry was done and airflow limitation was defined as having FEV1/FVC 
ratio <0.7. 
The level of awareness was in the middle range among 50% of porters according to our 
10 point awareness score and 36% fell in the low knowledge group. About 6% of porters 
had never heard of AMS. Porters were working two to three times a week from Lukla to 
Namche, up and down. They are the only means of goods transportation in this extreme 
corner of the world. Nevertheless, there is lack of awareness programmes. These porters 
have been struggling with this extreme environment plus poor socio-economic 
conditions. More awareness programmes regarding AMS will be beneficial for the 
porters and in the future, organizations working for p rters’ welfare should put forward 
various informative and awareness programmes in this region. 
The prevalence of AMS was 4% across all of our encou ters but increased with 
increasing altitude. Although, the prevalence was low compare to other studies among 
trekkers and climbers, AMS does occur among porters with frequency increasing with 
altitude.  
The prevalence of tobacco smoking in this group was34% though most were very light 
smokers. The prevalence of airflow limitation was 18% though it was not associated with 
smoking history. Open indoor fires for cooking, hyper-reactive airways disease and 
asthma might explain the high prevalence of airflow imitation. Awareness programmes 
against smoking might be an effective measure among this group as we found out that 
prevalence of respiratory symptoms were higher in the ex/current smokers. We 
recommend using modern stoves or cooking gases instead of open indoor fires for 
cooking if possible. 
Establishing health posts or primary health centers b tween Lukla and Base Camp with 
enough health personnel could be of further help as mo t porters considered health 




We would suggest a follow-up study using post-bronch dilator spirometry to determine 
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Appendix 1: Questionnaire for Awareness of Acute Mountain Sickness  
ID no# 
Part I 
1. Demographic Data 
A. Name: 
B. Age: C. Gender: 1) Male  2) Female D Birthdates:  
E. marital status: F. Education: G. Permanent Residence: H. Weight (KG): 
I. Height (cm): 
 
2. How do you work? 
A. Independently   B. with expeditions 
 
3. How many times have you been to Namche? 
 
4. How many times how you been to Everest base camp? 
 
5. Have you heard of Acute Mountain Sickness (AMS)? 
A. Yes   B. No 
If yes then answer 6 - 14 
6. If you have heard of AMS how did you? 
A. Friends  B. Books  C. Internet  D.Counselling 
  
E. Employer  F. Other _______ 
7.  What are the Signs and symptoms? 
A. Headache  B. Nausea  C. Fattigue  D. Dizziness 
 
8. What is the cause of AMS? 






9.  Do you ever have AMS? 
A. Yes   B. No  C. I don’t know 
 
10. If yes, how many times? 
A. One time  B. Two time  C. Three time  D.>Three time 
 
11. Where do you have it? 
Name of the place and will be later converted to height. 
 
12. Can AMS be prevented? 
A. Yes  B. No 
 
13. Can AMS be treated? 
A. Yes  B. No 
 
14. Is AMS a life threatening disease? 
A. Yes  B. No  C. I do not know 
 
15. Does the rate of ascent influence the occurrence of AMS? 
 A. Yes B. No  C. I do not know  
16. Have you ever attended Travel clinic? 
A. Yes  B. No 
 
17. If Yes, did you have counselling about AMS? 
A. Yes  B. No 
 
18. What will you do if you have headache during trek? 
A. Take medicine  B. Take herbal medicine  C. Nothing 
 
19. Are you carrying any medications with you?  







20. If yes 
A. Diamox  B. Pain-killers  C. Dexamethasone (or other steroid) D. 
Antibiotics 
 
21. Did you take any medications before your trip for prevention of AMS? 
A. Yes  B. No 
 
 
22. Do you think herbs can prevent AMS? 
A. Yes  B. No  C. I do not know 
 
23. How many years of trekking experience do you have as a porter? 
Number or year or estimate number of year 
 
24. What do you do if your partner/friend had AMS symptom during the trip? 
A. Go down at once B. Continue going up C. Take a break and stay at same place until 
symptoms pass. D. Don’t know or don’t what AMS is. 
 
25. Approximately, how many liters of water do you drink during a day? 
A. One liter  B. Two liters  C. Three liters  D. > Three liters 
 
26. Is it easy to get a good meal on the way? 
A. Yes  B. No 
 
27. How many times do you eat per day during the trip?   
A. One time  B. Two time  C. Three time  D.> Three time 
 
28. Are there any health post/ medical clinics on the way in case you got sick? 
A. Yes  B. No 
 
29. If yes, are there enough health personnel? 






30. Do you have easy access to medication in case you need for AMS?  
A. Yes              B. No 
 
31. How often do you take rest when you start going up? 
A. Less than hour  B. Every 1 hour C. Every 2 hour  D. Three or more 
hours  
 
32. How many hours do you sleep at night? 
A. < Four hour  B. Four hour  C. Six hour  D.> Six hour 
 
33. Do you drink alcohol? 
A. Yes  B. No 
 
34. If yes, do you drink daily? 
A. Yes  B. No 
 
35. Do you drink when you are working as a porter? 
A. Yes  B. No 
 
36. If yes, what kind of alcoholics drink you drink? 
A. Homemade/Local  B. Commercial 
 
37. How many glasses do you drink daily during your trip? 
A. Just one glass  B. Two glasses  C .Three glasses  
D. > Three glasses 
 
38. If you drink beer, how many bottles? 
A. One bottle (660ml)  B. Two bottles  C. Three bottles       D. >Three 
bottles 
 
39. Have you ever smoked tobacco cigarettes? 








40. Do you smoke now? 
A Yes  B no 
 
41. What age were you when you started smoking? ______ 
 
42.  If you have quit smoking, how old were you when you quit? 
 
43. How many sticks per day, do you smoke? 
 
       Number of cigarettes per day (or best estimate) 
 
44. Do you want to know more about AMS? 
A. Yes  B. It does not matter  C. No 
 
45. What do you think the best way to know about it? 







Experience of Working as Porter 
 
1. Are you paid well? 
A. Yes  B. No 
 
2. Is the income from work enough to survive? 
A. Yes  B. No 
 
3. Is your job risky? 
A. Yes  B. No 
 
4. Will you continue to work as porter, if you get another job in the same payment? 
A. Yes  B. No  
 
5. If yes, why? 
 
6. If no, why? 
 
7. If you are working as a porter in expedition team, do people take care of your 
health which might arise due to AMS or other medical causes? 
A. Yes  B. No 
 
8. Do you think it’s easy to tell your problem to the person responsible in case you 
got sick? 
A. Yes  B. No 
 
9. Do you have any language barrier with your guide/ with your expedition’s team? 
A. Yes  B. No 
 
10. Do you know of any organizations for your welfare? 





11. If yes. Do they help you in any kind of training or counseling for health 
problems that might arise during your trip as a porter? 
A. Yes  B. No 
 
12. Are you happy with your work as a porter? 


















Irritations from the airways 
1. Do you usually cough or clear your throat in the morning? 
A. Yes  B. No 
 
2.  Do you usually cough during the day? 
A. Yes  B. No 
 
3. Do you usually have phlegm when coughing? 
A. Yes  B. No 
 
4. Do you have cough for three months or more altogether during a year? 
A. Yes  B. No 
 
5. During the last two years, have you had cough and/or phlegm in connection with 
a cold for more than three weeks? 
A. Yes  B. One time      C. Several times      D. No 
 
6. Are you breathless than people of your own age when walking uphill? 
A. Yes  B. No 
 
7. Are you breathless when you climb two flights of stairs at an ordinary pace? 
A. Yes  B. No 
 
8. Are you breathless walking at a normal pace on level ground? 
A. Yes  B. No 
9. Are you breathless while at rest? 
A. Yes  B. No 
 
10. Do you sometime experience attacks of breathlessness? 
A. Yes  B. No 
 
11. Do you ever have wheezing (A wheezing sound) in your chest? 





12. Have you ever been treated by a physician or have you ever been hospitalized 
for one of the below mentioned diseases? 
A. Asthma    a) Yes  b) No  c) Don’t know 
B. Bronchitis    a) Yes  b) No  c) Don’t know 
C. Emphysema   a) Yes  b) No  c) Don’t know 
D. Pleuritis    a) Yes  b) No  c) Don’t know 
E. Pulmonary tuberculosis  a) Yes  b) No  c) Don’t k ow 
F. Heart infarction    a) Yes  b) No  c) Don’t know 
G. Angina pectoris       a) Yes  b) No  c) Don’t know 
I. Other heart diseases   a) Yes  b) No  c) Don’t know                                                                                              
 
 
Interviewed by:    Signature:    Date: 
 






Appendix 2: Questions used for AMS awareness score  
 
What are the Signs and symptoms of AMS?                      
 Headache          
 Nausea       
Fattigue    
 Dizziness 
     Yes           No 
      1              0 
      1              0 
      1              0 
      1              0 
What is the cause of AMS? 
 Vegetation          
 Altitude      
  Do not know 
     Yes           No 
      0              0 
      1              0 
      0              0 
 Can AMS be prevented?                                                               
Yes                  
No 
        
       1 
       0 
Can AMS be treated?   
                                                                                                   Yes                  
No 
       
       1 
       0 
Is AMS a life threatening disease?                                               
                                                                                                   Yes                  
No                  
I don’t know   
       
      1 
0
      0 
Does the rate of ascent influence the occurrence of AMS?                 Yes                  
No                  
I don’t know 
      1 
0
      0 
What do you do if your partner/friend had AMS symptom during the 
trip?   
 Go down at once   
 Continue going up      
 Take a break and stay at same place until symptoms pass.    
 Don’t know or don’t what AMS is. 
 
       
      0 
      0 
      1 




Appendix 3:  AMS worksheet in Nepali  
 
Based on the Lake Louise AMS Questionnaire  
Name______________________________________ Age ____ Sex____ Date 
____________ 
 
Prev Hx AMS/HAPE/HACE? 
Meds:  
 
Ascent Profile:  
Treatment: 
 
 Time ____ ____ ____ ____ 
 Altitude ____ ____ ____ ____ 
Symptoms: 
1. Headache: (Kapal Dukcha) 
 No headache (Dukdaina) 0 ____ ____ ____ ____ 
 Mild headache (Ali Ali Dukcha ) 1 ____ ____ ____ ____ 
 Moderate headache (Thikai Dukcha) 2 ____ ____ ____ ____ 
 Severe, incapacitating (Ekdam Dukcha) 3 ____ ____ ____ ____ 
 
2. GI: (Pet Ko Bare Lachyanharu) 
 No GI symptoms (Wak-Wak Chhaina, Bhok Lagcha) 0 ____ ____ ____  
 Poor appetite or nausea (Wak-Wak Lagcha, Bhok Chhaina) 1 ____ ____ ____  
 Moderate nausea or vomiting (Wak-Wak Ra Ali-Ali Banta ) 2 ____ ____ ____ _ 
 Severe N&V incapacitating (Dherai Banta) 3 ____ ____ ____ ____ 
 
3. Fatigue/weakness: (Thakai Lagne) 
 Not tired or weak (Thakai Chhaina) 0 ____ ____ ____ ____ 
 Mild fatigue/weakness (Alikati Thakai ) 1 ____ ____ ____ ____ 
 Moderate fatigue/weakness (Thikai-Thikai Thakai ) 2 ____ ____ ____ ____ 






4. Dizzy/lightheaded: (Ringata Lagne) 
 Not dizzy (Ringata Chhaina) 0 ____ ____ ____ ____ 
 Mild dizziness (Alikati Ringata ) 1 ____ ____ ____ ____ 
 Moderate dizziness (Thikai-Thikai Ringata ) 2 ____ ____ ____ ____ 
 Severe, incapacitating (Dherai Ringata) 3 ____ ____ ____ ____ 
 
5. Difficulty sleeping: (Sutna Garo) 
 Slept as well as usual (Ramrai Suteko) 0 ____ ____ ____ ____ 
 Did not sleep as well as usual (Ramrai Nasuteko) 1 ____ ____ ____ ____ 
 Woke many times, poor night's sleep (Dherai Choti Utheko) 2 ____ ____ ____  
 Could not sleep at all (Sutdai Nasuteko) 3 ____ ____ ____ ____ 
 
Symptom Score:  ____ ____ ____ ____ 
 
Clinical Assessment: 
6. Change in mental status: 
  No change 0 ____ ____ ____ ____ 
  Lethargy/lassitude 1 ____ ____ ____ ____ 
  Disoriented/confused 2 ____ ____ ____ ____ 
  Stupor/semi consciousness 3 ____ ____ ____ ____ 
7. Ataxia (heel to toe walking): 
  No ataxia 0 ____ ____ ____ ____ 
  Maneuvers to maintain balance 1 ____ ____ ____ __ 
  Steps off line 2 ____ ____ ____ ____ 
  Falls down 3 ____ ____ ____ ____ 
  Can't stand 4 ____ ____ ____ ____ 
8. Peripheral edema: 
  No edema 0 ____ ____ ____ ____ 
  One location 1 ____ ____ ____ ____ 
  Two or more locations 2 ____ ____ ____ ____ 
 
Clinical Assessment Score:   ____ ____ ____ ____ 
 





Appendix 4: Questionnaire wording for respiratory symptoms 
 
Cough 
Chronic cough  
Cough during day 
Cough with phlegm 
Cough more than three months during a year 
Cough more than three weeks during last two years in connection with cold 
 
Breathlessness 
Having to stop for breath and must stop for sometim before starting any activity again. 
Troubled by shortness of breath when hurrying or walking on normal pace on level 
ground. 
Troubled by shortness of breath when climbing two stair . 
Troubled by shortness of breath even at rest. 
 
Wheezing 
Whistling sound during inspiration which might be associated with cough and cold and 
any other airways symptoms. 
 
Past medical history 
Ever been treated or admitted to the hospital for any illness related to lung and heart such 
as asthma, bronchitis, pulmonary tuberculosis, Myocardial infarction. 
 
Smoking Habits 
Never-smokers were defined as individuals who had never smoked cigarette during their 
lifetime. 
Ex-smokers were defined as individual who smoked previously but had stopped smoking 
at the time of the study. 




Appendix 5: Oral consent form 
 
Questionnaire number:       Date: 
Title: Awareness and prevalence of acute mountain sickness and prevalence of 
obstructive airflow limitation among Nepalese porters: A cross-sectional 
study in Khumbu Valley, Nepal 
My name is Dr. Ranjan Parajuli. I am currently doing my Master of Philosophy in 
International Health at University of Bergen, Norway. As a part of programme, I am 
conducting a research designed to learn about “Awareness and prevalence of acute 
mountain sickness and prevalence of obstructive airflow limitation among Nepalese 
porters”. 
Purpose and background: A team of researcher from University of Bergen and 
Tribhuwan University Teaching Hospital, Kathmandu, Nepal affiliated to Mountain 
Medical Society of Nepal are studying awareness of acute mountain sickness and 
prevalence of acute mountain sickness and obstructive airflow limitation in this region 
among porters. 
Confidentiality : Your participation in the study is completely voluntary and confidential. 
Your name will not be connected with information you provide or the findings of our 
study. 
Benefits: The informations you provide during this interview may provide an overview 
of prevalence of acute mountain sickness and obstructive pulmonary disease and 
awareness of high altitude illness among porters in Khumbu valley or Everest region. 
This might be helpful for different organizations working for your benefits to improve 
their strategies and implicate new policies needed. 
If you have any questions about our research, I will answer them at any time. Again, your 
participation is completely voluntary and your responses to our questions will be anonymous.  




Appendix 6: Map of study site 
 
 
 
 
